Nyxoah price target raised to $14 from $10 at Cantor Fitzgerald

Cantor Fitzgerald analyst Ross Osborn raised the firm’s price target on Nyxoah to $14 from $10 and keeps an Overweight rating on the shares ahead of the readout for the DREAM study in Q2. Cantor believes the probability of positive data from DREAM and FDA approval is high and that there is a clear pathway to broad adoption in the U.S. driven by Genio’s differentiated design that allows for a single incision, external battery and better MRI compatibility, the analyst tells investors in a research note.